APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitor

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global PD-1 and PD-L1 Inhibitor Industry Growth and Trends Forecast to 2032

29 December 2025104 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitor Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitor Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitor Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitor Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global PD-1 and PD-L1 Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PD-1 and PD-L1 Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PD-1 and PD-L1 Inhibitor include Bristol Myers Squibb, Bristol-Myers Squibb, Regeneron Pharmaceuticals, AstraZeneca, Beigene, Hengrui Medicine, Pfizer, Junshi Biosciences and Akeso, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global PD-1 and PD-L1 Inhibitor market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The PD-1 and PD-L1 Inhibitor market size, estimates, and forecasts are presented in terms of sales volume (Tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global PD-1 and PD-L1 Inhibitor market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to PD-1 and PD-L1 Inhibitor.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global PD-1 and PD-L1 Inhibitor market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

PD-1 and PD-L1 Inhibitor Market by Company

Bristol Myers Squibb

Bristol-Myers Squibb

Regeneron Pharmaceuticals

AstraZeneca

Beigene

Hengrui Medicine

Pfizer

Junshi Biosciences

Akeso

Alphamab Oncology

Roche

Merck

Sanofi

Innovent Biologics

PD-1 and PD-L1 Inhibitor Segment by Type

Monoclonal Antibody

Bispecific Antibody

PD-1 and PD-L1 Inhibitor Segment by Application

Lung Cancer

Breast Cancer

Stomach Cancer

Rectal Cancer

Others

PD-1 and PD-L1 Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of PD-1 and PD-L1 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Monoclonal Antibody Table 2. Major Company of Bispecific Antibody Table 3. Global PD-1 and PD-L1 Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 5. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Type (2021-2026) Table 6. Global PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 7. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Type (2021-2026) Table 8. Global PD-1 and PD-L1 Inhibitor Price by Type (2021-2026) & (US$/Ton) Table 9. Global PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (Tons) Table 10. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Type (2027-2032) Table 11. Global PD-1 and PD-L1 Inhibitor Sales by Type (2027-2032) & (US$ Million) Table 12. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Type (2027-2032) Table 13. Global PD-1 and PD-L1 Inhibitor Price by Type (2027-2032) & (US$/Ton) Table 14. North America PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 15. North America PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 16. Europe PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 17. Europe PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 19. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 21. Latin America PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (Tons) Table 23. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 24. PD-1 and PD-L1 Inhibitor Industry Trends Table 25. PD-1 and PD-L1 Inhibitor Industry Drivers Table 26. PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges Table 27. PD-1 and PD-L1 Inhibitor Industry Restraints Table 28. Global PD-1 and PD-L1 Inhibitor Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Company (2021-2026) Table 30. Global PD-1 and PD-L1 Inhibitor Sales by Company (2021-2026) & (Tons) Table 31. Global PD-1 and PD-L1 Inhibitor Sales Share by Company (2021-2026) Table 32. Global PD-1 and PD-L1 Inhibitor Market Price by Company (2021-2026) & (US$/Ton) Table 33. Global PD-1 and PD-L1 Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global PD-1 and PD-L1 Inhibitor Major Company Production Sites and Headquarters Table 35. Global PD-1 and PD-L1 Inhibitor Company, Product Type & Application Table 36. Global PD-1 and PD-L1 Inhibitor Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global PD-1 and PD-L1 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global PD-1 and PD-L1 Inhibitor Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2026) & (Tons) Table 41. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Region (2021-2026) Table 42. Global PD-1 and PD-L1 Inhibitor Sales by Region (2021-2026) & (US$ Million) Table 43. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Region (2021-2026) Table 44. Global PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 45. Global PD-1 and PD-L1 Inhibitor Sales by Region (2027-2032) & (Tons) Table 46. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Region (2027-2032) Table 47. Global PD-1 and PD-L1 Inhibitor Sales by Region (2027-2032) & (US$ Million) Table 48. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Region (2027-2032) Table 49. Global PD-1 and PD-L1 Inhibitor Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2027-2032) Table 50. Global PD-1 and PD-L1 Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 52. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Application (2021-2026) Table 53. Global PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 54. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Application (2021-2026) Table 55. Global PD-1 and PD-L1 Inhibitor Price by Application (2021-2026) & (US$/Ton) Table 56. Global PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (Tons) Table 57. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Application (2027-2032) Table 58. Global PD-1 and PD-L1 Inhibitor Sales by Application (2027-2032) & (US$ Million) Table 59. Global PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Application (2027-2032) Table 60. Global PD-1 and PD-L1 Inhibitor Price by Application (2027-2032) & (US$/Ton) Table 61. North America PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 62. North America PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 63. Europe PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 64. Europe PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 66. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 68. Latin America PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (Tons) Table 70. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 71. Bristol Myers Squibb Company Information Table 72. Bristol Myers Squibb Business Overview Table 73. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 75. Bristol Myers Squibb Recent Development Table 76. Bristol-Myers Squibb Company Information Table 77. Bristol-Myers Squibb Business Overview Table 78. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio Table 80. Bristol-Myers Squibb Recent Development Table 81. Regeneron Pharmaceuticals Company Information Table 82. Regeneron Pharmaceuticals Business Overview Table 83. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio Table 85. Regeneron Pharmaceuticals Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio Table 90. AstraZeneca Recent Development Table 91. Beigene Company Information Table 92. Beigene Business Overview Table 93. Beigene PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Beigene PD-1 and PD-L1 Inhibitor Product Portfolio Table 95. Beigene Recent Development Table 96. Hengrui Medicine Company Information Table 97. Hengrui Medicine Business Overview Table 98. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio Table 100. Hengrui Medicine Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio Table 105. Pfizer Recent Development Table 106. Junshi Biosciences Company Information Table 107. Junshi Biosciences Business Overview Table 108. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 109. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio Table 110. Junshi Biosciences Recent Development Table 111. Akeso Company Information Table 112. Akeso Business Overview Table 113. Akeso PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 114. Akeso PD-1 and PD-L1 Inhibitor Product Portfolio Table 115. Akeso Recent Development Table 116. Alphamab Oncology Company Information Table 117. Alphamab Oncology Business Overview Table 118. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 119. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio Table 120. Alphamab Oncology Recent Development Table 121. Roche Company Information Table 122. Roche Business Overview Table 123. Roche PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 124. Roche PD-1 and PD-L1 Inhibitor Product Portfolio Table 125. Roche Recent Development Table 126. Merck Company Information Table 127. Merck Business Overview Table 128. Merck PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 129. Merck PD-1 and PD-L1 Inhibitor Product Portfolio Table 130. Merck Recent Development Table 131. Sanofi Company Information Table 132. Sanofi Business Overview Table 133. Sanofi PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 134. Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio Table 135. Sanofi Recent Development Table 136. Innovent Biologics Company Information Table 137. Innovent Biologics Business Overview Table 138. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 139. Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio Table 140. Innovent Biologics Recent Development Table 141. North America PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 142. North America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 143. North America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2026) Table 144. North America PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032) & (Tons) Table 145. North America PD-1 and PD-L1 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 146. North America PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. North America PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 148. North America PD-1 and PD-L1 Inhibitor Market Share by Country (2021-2026) Table 149. North America PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. North America PD-1 and PD-L1 Inhibitor Market Share Forecast by Country (2027-2032) Table 151. Europe PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 152. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 153. Europe PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2026) Table 154. Europe PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032) & (Tons) Table 155. Europe PD-1 and PD-L1 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 156. Europe PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Europe PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 158. Europe PD-1 and PD-L1 Inhibitor Market Share by Country (2021-2026) Table 159. Europe PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Europe PD-1 and PD-L1 Inhibitor Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 163. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2026) Table 164. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032) & (Tons) Table 165. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 168. Asia-Pacific PD-1 and PD-L1 Inhibitor Market Share by Country (2021-2026) Table 169. Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Asia-Pacific PD-1 and PD-L1 Inhibitor Market Share Forecast by Country (2027-2032) Table 171. Latin America PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 172. Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 173. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2026) Table 174. Latin America PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032) & (Tons) Table 175. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 176. Latin America PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Latin America PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 178. Latin America PD-1 and PD-L1 Inhibitor Market Share by Country (2021-2026) Table 179. Latin America PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Latin America PD-1 and PD-L1 Inhibitor Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (Tons): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026) & (Tons) Table 183. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2021-2026) Table 184. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032) & (Tons) Table 185. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 188. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Share by Country (2021-2026) Table 189. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Share Forecast by Country (2027-2032) Table 191. Key Raw Materials Table 192. Raw Materials Key Suppliers Table 193. PD-1 and PD-L1 Inhibitor Distributors List Table 194. PD-1 and PD-L1 Inhibitor Customers List Table 195. Research Programs/Design for This Report Table 196. Authors List of This Report Table 197. Secondary Sources Table 198. Primary Sources List of Figures Figure 1. PD-1 and PD-L1 Inhibitor Image Figure 2. Global PD-1 and PD-L1 Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1 and PD-L1 Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global PD-1 and PD-L1 Inhibitor Sales (2021-2032) & (Tons) Figure 5. Monoclonal Antibody Image Figure 6. Global Monoclonal Antibody Sales YoY Growth (2021-2032) & (Tons) Figure 7. Bispecific Antibody Image Figure 8. Global Bispecific Antibody Sales YoY Growth (2021-2032) & (Tons) Figure 9. Global PD-1 and PD-L1 Inhibitor Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global PD-1 and PD-L1 Inhibitor Market Share by Type 2025 VS 2032 Figure 11. North America PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 12. North America PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Type in 2025 Figure 13. Europe PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 14. Europe PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Type in 2025 Figure 17. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 18. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 PD-1 and PD-L1 Inhibitor Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Lung Cancer Image Figure 24. Global Lung Cancer Sales YoY Growth (2021-2032) & (Tons) Figure 25. Breast Cancer Image Figure 26. Global Breast Cancer Sales YoY Growth (2021-2032) & (Tons) Figure 27. Stomach Cancer Image Figure 28. Global Stomach Cancer Sales YoY Growth (2021-2032) & (Tons) Figure 29. Rectal Cancer Image Figure 30. Global Rectal Cancer Sales YoY Growth (2021-2032) & (Tons) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (Tons) Figure 33. Global PD-1 and PD-L1 Inhibitor Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global PD-1 and PD-L1 Inhibitor Market Share by Application 2025 VS 2032 Figure 35. North America PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 36. North America PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Application in 2025 Figure 37. Europe PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 38. Europe PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Application in 2025 Figure 41. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 42. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Market Share in Value by Application in 2025 Figure 45. North America PD-1 and PD-L1 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 46. North America PD-1 and PD-L1 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America PD-1 and PD-L1 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe PD-1 and PD-L1 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 50. Europe PD-1 and PD-L1 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe PD-1 and PD-L1 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 54. Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific PD-1 and PD-L1 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America PD-1 and PD-L1 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 58. Latin America PD-1 and PD-L1 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America PD-1 and PD-L1 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (Tons) Figure 62. Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa PD-1 and PD-L1 Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. PD-1 and PD-L1 Inhibitor Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. PD-1 and PD-L1 Inhibitor Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • Bispecific Antibody
Applications
  • Lung Cancer
  • Breast Cancer
  • Stomach Cancer
  • Rectal Cancer
  • Others
Companies covered
  • Bristol Myers Squibb
  • Bristol-Myers Squibb
  • Regeneron Pharmaceuticals
  • AstraZeneca
  • Beigene
  • Hengrui Medicine
  • Pfizer
  • Junshi Biosciences
  • Akeso
  • Alphamab Oncology
  • Roche
  • Merck
  • Sanofi
  • Innovent Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PD-1 and PD-L1 Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global PD-1 and PD-L1 Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.3 PD-1 and PD-L1 Inhibitor Market by Type
  6. 1.3.1 Monoclonal Antibody
  7. 1.3.2 Bispecific Antibody
  8. 1.4 Global PD-1 and PD-L1 Inhibitor Market Size by Type
  9. 1.4.1 Global PD-1 and PD-L1 Inhibitor Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global PD-1 and PD-L1 Inhibitor Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global PD-1 and PD-L1 Inhibitor Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America PD-1 and PD-L1 Inhibitor Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe PD-1 and PD-L1 Inhibitor Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America PD-1 and PD-L1 Inhibitor Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 PD-1 and PD-L1 Inhibitor Industry Trends
  2. 2.2 PD-1 and PD-L1 Inhibitor Industry Drivers
  3. 2.3 PD-1 and PD-L1 Inhibitor Industry Opportunities and Challenges
  4. 2.4 PD-1 and PD-L1 Inhibitor Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by PD-1 and PD-L1 Inhibitor Revenue (2021-2026)
  2. 3.2 Global Top Players by PD-1 and PD-L1 Inhibitor Sales (2021-2026)
  3. 3.3 Global Top Players by PD-1 and PD-L1 Inhibitor Price (2021-2026)
  4. 3.4 Global PD-1 and PD-L1 Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PD-1 and PD-L1 Inhibitor Major Company Production Sites & Headquarters
  6. 3.6 Global PD-1 and PD-L1 Inhibitor Company, Product Type & Application
  7. 3.7 Global PD-1 and PD-L1 Inhibitor Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PD-1 and PD-L1 Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PD-1 and PD-L1 Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PD-1 and PD-L1 Inhibitor Tier 1, Tier 2, and Tier 3
4 PD-1 and PD-L1 Inhibitor Regional Status and Outlook
  1. 4.1 Global PD-1 and PD-L1 Inhibitor Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global PD-1 and PD-L1 Inhibitor Historic Market Size by Region
  3. 4.2.1 Global PD-1 and PD-L1 Inhibitor Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global PD-1 and PD-L1 Inhibitor Sales in Value by Region (2021-2026)
  5. 4.2.3 Global PD-1 and PD-L1 Inhibitor Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global PD-1 and PD-L1 Inhibitor Forecasted Market Size by Region
  7. 4.3.1 Global PD-1 and PD-L1 Inhibitor Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global PD-1 and PD-L1 Inhibitor Sales in Value by Region (2027-2032)
  9. 4.3.3 Global PD-1 and PD-L1 Inhibitor Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 PD-1 and PD-L1 Inhibitor by Application
  1. 5.1 PD-1 and PD-L1 Inhibitor Market by Application
  2. 5.1.1 Lung Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Stomach Cancer
  5. 5.1.4 Rectal Cancer
  6. 5.1.5 Others
  7. 5.2 Global PD-1 and PD-L1 Inhibitor Market Size by Application
  8. 5.2.1 Global PD-1 and PD-L1 Inhibitor Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global PD-1 and PD-L1 Inhibitor Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global PD-1 and PD-L1 Inhibitor Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America PD-1 and PD-L1 Inhibitor Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe PD-1 and PD-L1 Inhibitor Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America PD-1 and PD-L1 Inhibitor Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Bristol Myers Squibb
  2. 6.1.1 Bristol Myers Squibb Company Information
  3. 6.1.2 Bristol Myers Squibb Business Overview
  4. 6.1.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  6. 6.1.5 Bristol Myers Squibb Recent Developments
  7. 6.2 Bristol-Myers Squibb
  8. 6.2.1 Bristol-Myers Squibb Company Information
  9. 6.2.2 Bristol-Myers Squibb Business Overview
  10. 6.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
  12. 6.2.5 Bristol-Myers Squibb Recent Developments
  13. 6.3 Regeneron Pharmaceuticals
  14. 6.3.1 Regeneron Pharmaceuticals Company Information
  15. 6.3.2 Regeneron Pharmaceuticals Business Overview
  16. 6.3.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio
  18. 6.3.5 Regeneron Pharmaceuticals Recent Developments
  19. 6.4 AstraZeneca
  20. 6.4.1 AstraZeneca Company Information
  21. 6.4.2 AstraZeneca Business Overview
  22. 6.4.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio
  24. 6.4.5 AstraZeneca Recent Developments
  25. 6.5 Beigene
  26. 6.5.1 Beigene Company Information
  27. 6.5.2 Beigene Business Overview
  28. 6.5.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio
  30. 6.5.5 Beigene Recent Developments
  31. 6.6 Hengrui Medicine
  32. 6.6.1 Hengrui Medicine Company Information
  33. 6.6.2 Hengrui Medicine Business Overview
  34. 6.6.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio
  36. 6.6.5 Hengrui Medicine Recent Developments
  37. 6.7 Pfizer
  38. 6.7.1 Pfizer Company Information
  39. 6.7.2 Pfizer Business Overview
  40. 6.7.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio
  42. 6.7.5 Pfizer Recent Developments
  43. 6.8 Junshi Biosciences
  44. 6.8.1 Junshi Biosciences Company Information
  45. 6.8.2 Junshi Biosciences Business Overview
  46. 6.8.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio
  48. 6.8.5 Junshi Biosciences Recent Developments
  49. 6.9 Akeso
  50. 6.9.1 Akeso Company Information
  51. 6.9.2 Akeso Business Overview
  52. 6.9.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio
  54. 6.9.5 Akeso Recent Developments
  55. 6.10 Alphamab Oncology
  56. 6.10.1 Alphamab Oncology Company Information
  57. 6.10.2 Alphamab Oncology Business Overview
  58. 6.10.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio
  60. 6.10.5 Alphamab Oncology Recent Developments
  61. 6.11 Roche
  62. 6.11.1 Roche Company Information
  63. 6.11.2 Roche Business Overview
  64. 6.11.3 Roche PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio
  66. 6.11.5 Roche Recent Developments
  67. 6.12 Merck
  68. 6.12.1 Merck Company Information
  69. 6.12.2 Merck Business Overview
  70. 6.12.3 Merck PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio
  72. 6.12.5 Merck Recent Developments
  73. 6.13 Sanofi
  74. 6.13.1 Sanofi Company Information
  75. 6.13.2 Sanofi Business Overview
  76. 6.13.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio
  78. 6.13.5 Sanofi Recent Developments
  79. 6.14 Innovent Biologics
  80. 6.14.1 Innovent Biologics Company Information
  81. 6.14.2 Innovent Biologics Business Overview
  82. 6.14.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio
  84. 6.14.5 Innovent Biologics Recent Developments
7 North America by Country
  1. 7.1 North America PD-1 and PD-L1 Inhibitor Sales by Country
  2. 7.1.1 North America PD-1 and PD-L1 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026)
  4. 7.1.3 North America PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032)
  5. 7.2 North America PD-1 and PD-L1 Inhibitor Market Size by Country
  6. 7.2.1 North America PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026)
  8. 7.2.3 North America PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe PD-1 and PD-L1 Inhibitor Sales by Country
  2. 8.1.1 Europe PD-1 and PD-L1 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026)
  4. 8.1.3 Europe PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032)
  5. 8.2 Europe PD-1 and PD-L1 Inhibitor Market Size by Country
  6. 8.2.1 Europe PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026)
  8. 8.2.3 Europe PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific PD-1 and PD-L1 Inhibitor Sales by Country
  2. 9.1.1 Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size by Country
  6. 9.2.1 Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America PD-1 and PD-L1 Inhibitor Sales by Country
  2. 10.1.1 South America PD-1 and PD-L1 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026)
  4. 10.1.3 South America PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032)
  5. 10.2 South America PD-1 and PD-L1 Inhibitor Market Size by Country
  6. 10.2.1 South America PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026)
  8. 10.2.3 South America PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country
  2. 11.1.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country
  6. 11.2.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 PD-1 and PD-L1 Inhibitor Value Chain Analysis
  2. 12.1.1 PD-1 and PD-L1 Inhibitor Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 PD-1 and PD-L1 Inhibitor Production Mode & Process
  7. 12.2 PD-1 and PD-L1 Inhibitor Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 PD-1 and PD-L1 Inhibitor Distributors
  10. 12.2.3 PD-1 and PD-L1 Inhibitor Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst